Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenal Gland Disorders

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Goiter

Goiter

Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...

Cushing Syndrome I: Introduction

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effects of various peptides on human isolated gut muscle.

The Journal of pharmacy and pharmacology·1992

Same author

The presence, characterisation and synthesis of neuromedin B in the human pituitary gland.

Neuroendocrinology·1992

Same author

Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide.

The American journal of physiology·1992

Same author

Expression of messenger ribonucleic acids encoding neuropeptide-Y, substance-P, and vasoactive intestinal polypeptide in human pituitary.

The Journal of clinical endocrinology and metabolism·1992

Same author

The presence of neuropeptides in GABAergic and cholinergic rat cerebrocortical synaptosome sub-populations.

Neuropeptides·1992

Same author

Characterization of complementary DNA encoding the rat neuromedin U precursor.

Molecular endocrinology (Baltimore, Md.)·1992

Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026

Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026

Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026

Same journal

Practice Changing Updates in Perioperative Medicine Literature 2025. A Systematic Review.

The American journal of medicine·2026

Same journal

Risk of Infection-Related Hospitalization Is More Than Doubled in Cushing's Syndrome vs Matched Controls.

The American journal of medicine·2026

Same journal

Chronic Inflammatory Diseases and Survival among Patients with Pancreatic Cancer in the U.S. Military Health System.

The American journal of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Acromegaly.

The American Journal of Medicine

|May 29, 1987

Summary

This summary is machine-generated.

A long-acting somatostatin analogue, SMS 201-995, effectively manages acromegaly by inhibiting growth hormone release. This palliative treatment offers long-term symptom remission with minimal side effects for patients with pituitary macroadenomas.

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Related Experiment Videos

Last Updated: Jun 22, 2026

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Area of Science:

Endocrinology
Pharmacology

Background:

Acromegaly is often diagnosed with large pituitary adenomas (>1 cm).
Current treatments like surgery and radiotherapy have limited cure rates for pituitary macroadenomas.
Natural somatostatin inhibits growth hormone release but has a very short plasma half-life.

Purpose of the Study:

To evaluate the efficacy of a long-acting somatostatin analogue, SMS 201-995, in managing acromegaly.
To assess the potential of SMS 201-995 as a palliative treatment for pituitary macroadenomas.

Main Methods:

Patients self-administered SMS 201-995 two to three times daily at home.
Long-term treatment outcomes were monitored.

Main Results:

SMS 201-995 demonstrated long-term inhibition of growth hormone release.
Clinical symptoms of acromegaly showed remission in patients undergoing treatment.
The treatment was associated with no significant side effects.

Conclusions:

SMS 201-995 is a viable and effective palliative treatment for acromegaly.
Prolonged therapy with SMS 201-995 can lead to sustained control of growth hormone levels and acromegaly symptoms.
Self-administration of SMS 201-995 offers a practical therapeutic option for acromegaly management.